{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:51:12Z","timestamp":1790268672451,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019592","name":"Veterans Administration Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.aohep.2023.100899","type":"journal-article","created":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T09:45:08Z","timestamp":1673171108000},"page":"100899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of elbasvir\/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance"],"prefix":"10.1016","volume":"28","author":[{"given":"Deanna D.","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassie R.","family":"Chaffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Christopher","family":"Mast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fasiha","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.aohep.2023.100899_bib0001","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.100899_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100391","article-title":"Department of Veterans Affairs (VA) as a model for stronger public health infrastructure to combat HCV and other infectious diseases and reduce disparities","volume":"22","author":"McGinnis","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.aohep.2023.100899_bib0003","first-page":"24","article-title":"Screening and treating hepatitis C in the VA: achieving excellence using lean and system redesign","volume":"35","author":"Park","year":"2018","journal-title":"Fed Pract"},{"key":"10.1016\/j.aohep.2023.100899_bib0004","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/epirev\/mxu002","article-title":"Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs","volume":"37","author":"Beste","year":"2015","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.aohep.2023.100899_bib0005","unstructured":"Merck & Co. Inc. ZEPATIER\u00ae (elbasvir and grazoprevir) tablets, for oral use. Rahway, NJ, USA: Merck Sharp & Dohme LLC; 06\/2018."},{"issue":"1","key":"10.1016\/j.aohep.2023.100899_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.aohep.2023.100899_bib0007","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.gastro.2016.09.045","article-title":"Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection","volume":"152","author":"Kwo","year":"2017","journal-title":"Gastroenterology"},{"issue":"10003","key":"10.1016\/j.aohep.2023.100899_bib0008","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.aohep.2023.100899_bib0009","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.aohep.2023.100899_bib0010","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/hep.29139","article-title":"Elbasvir\/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study","volume":"66","author":"H\u00e9zode","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.100899_bib0011","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2017.01.050","article-title":"Safety and efficacy of elbasvir\/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis","volume":"152","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2023.100899_bib0012","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/liv.13727","article-title":"Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.aohep.2023.100899_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.aohep.2023.100899_bib0014","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/jvh.12937","article-title":"Real-world effectiveness of elbasvir\/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system","volume":"25","author":"Kramer","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.aohep.2023.100899_bib0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.antiviral.2018.10.003","article-title":"Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: a multicenter, real-world cohort study focusing on chronic kidney disease","volume":"159","author":"Ogawa","year":"2018","journal-title":"Antiviral Res"},{"issue":"12","key":"10.1016\/j.aohep.2023.100899_bib0016","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00535-018-1473-z","article-title":"Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan","volume":"53","author":"Toyoda","year":"2018","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.aohep.2023.100899_bib0017","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jvh.13008","article-title":"Effectiveness and safety of elbasvir\/grazoprevir therapy in patients with chronic HCV infection: results from the Spanish HEPA-C real-world cohort","volume":"26","author":"Hernandez-Conde","year":"2019","journal-title":"J Viral Hepat"},{"issue":"11","key":"10.1016\/j.aohep.2023.100899_bib0018","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/apt.14635","article-title":"Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network","volume":"47","author":"Flamm","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2023.100899_bib0019","series-title":"Zepatier EMA Committee for Medicinal Products for Human Use (CHMP) assessment report","year":"2016"},{"issue":"3","key":"10.1016\/j.aohep.2023.100899_bib0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jvh.13037","article-title":"The accuracy of baseline viral load for predicting the efficacy of elbasvir\/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis","volume":"26","author":"Serfaty","year":"2019","journal-title":"J Viral Hepat"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268123000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268123000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:45:01Z","timestamp":1761648301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268123000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1665268123000030"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2023.100899","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of elbasvir\/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2023.100899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier Spain.","name":"copyright","label":"Copyright"}],"article-number":"100899"}}